X4 Pharma Q3 net loss $36.7M; positive Phase 2 CN data; XOLREMDI launch underway

X4 Pharmaceuticals, Inc

2024-Q3 EPS reported $0.01 revenue$1,123,000

Q3 net loss $36.7M vs $2.3M loss in Q3 2023; includes $1.9M non-cash loss on warrant liability.
Net product revenue of $0.6M from XOLREMDI (mavorixafor) for WHIM syndrome, launched April 2024.
Positive Phase 2 results: mavorixafor durably increased absolute neutrophil counts and enabled G-CSF reduction in chronic neutropenia.
Phase 3 4WARD trial on track to fully enroll mid-2025; regulatory approvals in ~85% of targeted countries.
Cash $135.8M, sufficient into late 2025 (excludes potential XOLREMDI revenue).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.